FGFR2 and cholangiocarcinoma: Durations of treatment and follow‐up were relatively short as of the data cutoff, limiting time‐to‐event and safety assessments; the mature OS data will provide additional evidence for efficacy of pemigatinib in Chinese patients with cholangiocarcinoma and FGFR2 rearrangements.